Incannex to present at the h.c. wainwright first annual mental health conference

Melbourne, australia , june 27, 2022 /prnewswire/ -- incannex healthcare limited (nasdaq: ixhl) (asx: ihl), ('incannex' or the 'company') a clinical-stage pharmaceutical company developing unique medicinal cannabinoid pharmaceutical products and psychedelic medicine therapies for unmet medical needs, today announced that dr. paul liknaitzky, head of clinical psychedelic research at monash university and chief principal investigator for incannex's psilocybin-assisted psychotherapy, will present an overview of progress achieved in incannex's psychedelic medicine program at the h.c. wainwright first annual mental health conference, taking place june 27, 2022.
IXHL Ratings Summary
IXHL Quant Ranking